21,000 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Ausdal Financial Partners Inc.

Ausdal Financial Partners Inc. bought a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRNFree Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 21,000 shares of the company’s stock, valued at approximately $214,000.

Several other institutional investors also recently made changes to their positions in SLRN. Marshall Wace LLP acquired a new stake in shares of Acelyrin during the 2nd quarter valued at $24,276,000. Driehaus Capital Management LLC acquired a new position in Acelyrin during the second quarter worth $36,759,000. CHI Advisors LLC acquired a new position in Acelyrin during the second quarter worth $55,674,000. Strs Ohio acquired a new position in Acelyrin during the third quarter worth $71,000. Finally, TD Asset Management Inc bought a new stake in Acelyrin during the second quarter valued at about $1,288,000. 94.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on SLRN shares. Wells Fargo & Company started coverage on shares of Acelyrin in a report on Wednesday, December 13th. They set an “equal weight” rating and a $11.00 price target for the company. Morgan Stanley decreased their price target on shares of Acelyrin from $19.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, November 29th. Citigroup began coverage on shares of Acelyrin in a research note on Friday, December 8th. They issued a “neutral” rating and a $8.00 target price for the company. Jefferies Financial Group dropped their price target on shares of Acelyrin from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday, November 28th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Acelyrin in a research report on Tuesday, November 28th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.67.

Read Our Latest Stock Analysis on SLRN

Insider Activity at Acelyrin

In related news, CEO Shao-Lee Lin sold 10,691 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $7.41, for a total value of $79,220.31. Following the completion of the sale, the chief executive officer now owns 1,603,036 shares of the company’s stock, valued at $11,878,496.76. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Acelyrin Stock Down 2.2 %

NASDAQ SLRN opened at $8.01 on Friday. The company has a 50 day moving average of $7.26 and a 200-day moving average of $12.66. Acelyrin, Inc. has a 1-year low of $5.70 and a 1-year high of $29.88.

Acelyrin (NASDAQ:SLRNGet Free Report) last issued its quarterly earnings results on Tuesday, November 7th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.40). Sell-side analysts expect that Acelyrin, Inc. will post -7.4 earnings per share for the current year.

Acelyrin Company Profile

(Free Report)

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.

See Also

Want to see what other hedge funds are holding SLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acelyrin, Inc. (NASDAQ:SLRNFree Report).

Institutional Ownership by Quarter for Acelyrin (NASDAQ:SLRN)

Receive News & Ratings for Acelyrin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acelyrin and related companies with MarketBeat.com's FREE daily email newsletter.